CAMBRIDGE, Thursday 1 June 2023 — bit.bio was featured in an article in Forbes by Senior Contributor and Synthetic biology author John Cumbers.
The piece, titled "Meet The Company Democratising Access To Human Cells" covers the launch of bit.bio's Custom ioDisease Model CellsTM offering at the SynBioBeta conference and how this offer has incredible potential for rare diseases, where conventional drug discovery methods often fall short. The piece also features Everlum.bio, who are already using bit.bio's cells to develop therapies for rare diseases.
Access the full article here.